Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 28 |
| List of Tables | 25 | 4 |
| List of Figures | 29 | 1 |
| Introduction | 30 | 1 |
| Global Markets Direct Report Coverage | 30 | 1 |
| Hypertension Overview | 31 | 1 |
| Therapeutics Development | 32 | 2 |
| Pipeline Products for Hypertension Overview | 32 | 1 |
| Pipeline Products for Hypertension Comparative Analysis | 33 | 1 |
| Hypertension Therapeutics under Development by Companies | 34 | 9 |
| Hypertension Therapeutics under Investigation by Universities/Institutes | 43 | 2 |
| Hypertension Pipeline Products Glance | 45 | 3 |
| Late Stage Products | 45 | 1 |
| Clinical Stage Products | 46 | 1 |
| Early Stage Products | 47 | 1 |
| Hypertension Products under Development by Companies | 48 | 13 |
| Hypertension Products under Investigation by Universities/Institutes | 61 | 2 |
| Hypertension Companies Involved in Therapeutics Development | 63 | 100 |
| A1M Pharma AB | 63 | 1 |
| AbbVie Inc. | 64 | 1 |
| Ache Laboratorios Farmaceuticos S/A | 65 | 1 |
| Actelion Ltd | 66 | 1 |
| Afferent Pharmaceuticals, Inc. | 67 | 1 |
| Allergan Plc | 68 | 1 |
| Alnylam Pharmaceuticals, Inc. | 69 | 1 |
| Anacor Pharmaceuticals, Inc. | 70 | 1 |
| APT Therapeutics, Inc. | 71 | 1 |
| Arena Pharmaceuticals, Inc. | 72 | 1 |
| Ascendis Pharma A/S | 73 | 1 |
| AVEO Pharmaceuticals, Inc. | 74 | 1 |
| Bayer AG | 75 | 1 |
| Bial - Portela &Ca, S.A. | 76 | 1 |
| Bio-inRen | 77 | 1 |
| BioRestorative Therapies, Inc. | 78 | 1 |
| Bristol-Myers Squibb Company | 79 | 1 |
| Cellceutix Corporation | 80 | 1 |
| Celsion Corporation | 81 | 1 |
| Celtaxsys, Inc. | 82 | 1 |
| Chong Kun Dang Pharmaceutical Corp. | 83 | 1 |
| CJ HealthCare Corp. | 84 | 1 |
| Complexa, Inc. | 85 | 1 |
| Conatus Pharmaceuticals Inc. | 86 | 1 |
| Cytokinetics, Inc. | 87 | 1 |
| Daewoong Pharmaceutical Co., Ltd. | 88 | 1 |
| Daiichi Sankyo Company, Limited | 89 | 1 |
| DiaMedica Inc. | 90 | 1 |
| Eli Lilly and Company | 91 | 1 |
| Esperion Therapeutics, Inc. | 92 | 1 |
| F. Hoffmann-La Roche Ltd. | 93 | 1 |
| Galectin Therapeutics, Inc. | 94 | 1 |
| Genextra S.p.a. | 95 | 1 |
| Gilead Sciences, Inc. | 96 | 1 |
| GlaxoSmithKline Plc | 97 | 1 |
| Glenveigh Medical, LLC | 98 | 1 |
| HanAll Biopharma Co., Ltd. | 99 | 1 |
| Hanmi Pharmaceuticals, Co. Ltd. | 100 | 1 |
| HitGen LTD | 101 | 1 |
| Innopharmax Inc. | 102 | 1 |
| Insmed Incorporated | 103 | 1 |
| INVENT Pharmaceuticals, Inc. | 104 | 1 |
| Ionis Pharmaceuticals, Inc. | 105 | 1 |
| Jeil Pharmaceutical Co., Ltd. | 106 | 1 |
| Johnson &Johnson | 107 | 1 |
| JW Pharmaceutical Corporation | 108 | 1 |
| Kowa Company, Ltd. | 109 | 1 |
| Lee's Pharmaceutical Holdings Limited | 110 | 1 |
| Les Laboratoires Servier SAS | 111 | 1 |
| LFB S.A. | 112 | 1 |
| LG Life Science LTD. | 113 | 1 |
| LinXis B.V. | 114 | 1 |
| Lotus Pharmaceutical Co., Ltd. | 115 | 1 |
| Mallinckrodt Plc | 116 | 1 |
| Mast Therapeutics, Inc. | 117 | 1 |
| Merck &Co., Inc. | 118 | 1 |
| Mezzion Pharma Co. Ltd. | 119 | 1 |
| miRagen Therapeutics, Inc. | 120 | 1 |
| Mitsubishi Tanabe Pharma Corporation | 121 | 1 |
| Morphogen-IX Limited | 122 | 1 |
| Neurim Pharmaceuticals Ltd | 123 | 1 |
| Nippon Kayaku Co., Ltd. | 124 | 1 |
| Nippon Shinyaku Co., Ltd. | 125 | 1 |
| Novartis AG | 126 | 1 |
| Noxamet Ltd | 127 | 1 |
| Omeros Corporation | 128 | 1 |
| Ono Pharmaceutical Co., Ltd. | 129 | 1 |
| Peloton Therapeutics, Inc. | 130 | 1 |
| Pfizer Inc. | 131 | 1 |
| PhaseBio Pharmaceuticals, Inc. | 132 | 1 |
| Pluristem Therapeutics Inc. | 133 | 1 |
| Proteo, Inc. | 134 | 1 |
| Pulmokine, Inc. | 135 | 1 |
| Quantum Genomics SA | 136 | 1 |
| Reata Pharmaceuticals, Inc. | 137 | 1 |
| RedHill Biopharma Ltd. | 138 | 1 |
| Respira Therapeutics, Inc. | 139 | 1 |
| Reviva Pharmaceuticals Inc. | 140 | 1 |
| Sanofi | 141 | 1 |
| Selten Pharma, Inc | 142 | 1 |
| Serodus ASA | 143 | 1 |
| Shanghai Pharmaceutical Co., Ltd. | 144 | 1 |
| Sihuan Pharmaceutical Holdings Group Ltd. | 145 | 1 |
| Silence Therapeutics Plc | 146 | 1 |
| Simcere Pharmaceutical Group | 147 | 1 |
| SteadyMed Therapeutics, Inc. | 148 | 1 |
| Suda Ltd | 149 | 1 |
| Sumitomo Dainippon Pharma Co., Ltd. | 150 | 1 |
| Takeda Pharmaceutical Company Limited | 151 | 1 |
| The Medicines Company | 152 | 1 |
| Theravance Biopharma, Inc. | 153 | 1 |
| Toray Industries, Inc. | 154 | 1 |
| Torrent Pharmaceuticals Limited | 155 | 1 |
| TSH Biopharm Corporation Limited | 156 | 1 |
| vasopharm GmbH | 157 | 1 |
| VBS Pharmaceuticals | 158 | 1 |
| Vectura Group Plc | 159 | 1 |
| VG Life Sciences, Inc. | 160 | 1 |
| Vicore Pharma AB | 161 | 1 |
| Yuhan Corporation | 162 | 1 |
| Hypertension Therapeutics Assessment | 163 | 20 |
| Assessment by Monotherapy Products | 163 | 1 |
| Assessment by Combination Products | 164 | 1 |
| Assessment by Target | 165 | 8 |
| Assessment by Mechanism of Action | 173 | 6 |
| Assessment by Route of Administration | 179 | 2 |
| Assessment by Molecule Type | 181 | 2 |
| Drug Profiles | 183 | 382 |
| (amlodipine + olmesartan medoxomil) - Drug Profile | 183 | 1 |
| Product Description | 183 | 1 |
| Mechanism of Action | 183 | 1 |
| R&D Progress | 183 | 1 |
| (amlodipine besylate + atorvastatin calcium + valsartan) - Drug Profile | 184 | 1 |
| Product Description | 184 | 1 |
| Mechanism of Action | 184 | 1 |
| R&D Progress | 184 | 1 |
| (amlodipine besylate + azilsartan medoxomil + hydrochlorothiazide) - Drug Profile | 185 | 1 |
| Product Description | 185 | 1 |
| Mechanism of Action | 185 | 1 |
| R&D Progress | 185 | 1 |
| (amlodipine besylate + candesartan cilexetil) - Drug Profile | 186 | 1 |
| Product Description | 186 | 1 |
| Mechanism of Action | 186 | 1 |
| R&D Progress | 186 | 1 |
| (amlodipine besylate + candesartan cilexetil) - Drug Profile | 187 | 1 |
| Product Description | 187 | 1 |
| Mechanism of Action | 187 | 1 |
| R&D Progress | 187 | 1 |
| (amlodipine besylate + candesartan cilexetil) - Drug Profile | 188 | 1 |
| Product Description | 188 | 1 |
| Mechanism of Action | 188 | 1 |
| R&D Progress | 188 | 1 |
| (amlodipine besylate + celecoxib) - Drug Profile | 189 | 2 |
| Product Description | 189 | 1 |
| Mechanism of Action | 189 | 1 |
| R&D Progress | 189 | 2 |
| (amlodipine besylate + indapamide + perindopril) - Drug Profile | 191 | 1 |
| Product Description | 191 | 1 |
| Mechanism of Action | 191 | 1 |
| R&D Progress | 191 | 1 |
| (amlodipine besylate + irbesartan) - Drug Profile | 192 | 1 |
| Product Description | 192 | 1 |
| Mechanism of Action | 192 | 1 |
| R&D Progress | 192 | 1 |
| (amlodipine besylate + perindopril) - Drug Profile | 193 | 2 |
| Product Description | 193 | 1 |
| Mechanism of Action | 193 | 1 |
| R&D Progress | 193 | 2 |
| (amlodipine besylate + rosuvastatin calcium + valsartan) - Drug Profile | 195 | 1 |
| Product Description | 195 | 1 |
| Mechanism of Action | 195 | 1 |
| R&D Progress | 195 | 1 |
| (amlodipine besylate + rosuvastatin calcium) - Drug Profile | 196 | 1 |
| Product Description | 196 | 1 |
| Mechanism of Action | 196 | 1 |
| R&D Progress | 196 | 1 |
| (amlodipine maleate + chlorthalidone + telmisartan) - Drug Profile | 197 | 1 |
| Product Description | 197 | 1 |
| Mechanism of Action | 197 | 1 |
| R&D Progress | 197 | 1 |
| (amlodipine maleate + dextromethorphan hydrobromide) - Drug Profile | 198 | 1 |
| Product Description | 198 | 1 |
| Mechanism of Action | 198 | 1 |
| R&D Progress | 198 | 1 |
| (aspirin + lisinopril + lovastatin) - Drug Profile | 199 | 1 |
| Product Description | 199 | 1 |
| Mechanism of Action | 199 | 1 |
| R&D Progress | 199 | 1 |
| (atorvastatin calcium + losartan potassium) - Drug Profile | 200 | 1 |
| Product Description | 200 | 1 |
| Mechanism of Action | 200 | 1 |
| R&D Progress | 200 | 1 |
| (atorvastatin calcium + perindopril) - Drug Profile | 201 | 1 |
| Product Description | 201 | 1 |
| Mechanism of Action | 201 | 1 |
| R&D Progress | 201 | 1 |
| (candesartan cilexetil + metformin hydrochloride) - Drug Profile | 202 | 1 |
| Product Description | 202 | 1 |
| Mechanism of Action | 202 | 1 |
| R&D Progress | 202 | 1 |
| (candesartan cilexetil + nifedipine) - Drug Profile | 203 | 1 |
| Product Description | 203 | 1 |
| Mechanism of Action | 203 | 1 |
| R&D Progress | 203 | 1 |
| (candesartan cilexetil + rosuvastatin calcium) - Drug Profile | 204 | 1 |
| Product Description | 204 | 1 |
| Mechanism of Action | 204 | 1 |
| R&D Progress | 204 | 1 |
| (chlorthalidone + telmisartan) - Drug Profile | 205 | 1 |
| Product Description | 205 | 1 |
| Mechanism of Action | 205 | 1 |
| R&D Progress | 205 | 1 |
| (chlorthalidone + valsartan) - Drug Profile | 206 | 1 |
| Product Description | 206 | 1 |
| Mechanism of Action | 206 | 1 |
| R&D Progress | 206 | 1 |
| (indapamide + perindopril) - Drug Profile | 207 | 1 |
| Product Description | 207 | 1 |
| Mechanism of Action | 207 | 1 |
| R&D Progress | 207 | 1 |
| (lercanidipine hydrochloride + valsartan) - Drug Profile | 208 | 1 |
| Product Description | 208 | 1 |
| Mechanism of Action | 208 | 1 |
| R&D Progress | 208 | 1 |
| (levamlodipine + rosuvastatin calcium + telmisartan) - Drug Profile | 209 | 1 |
| Product Description | 209 | 1 |
| Mechanism of Action | 209 | 1 |
| R&D Progress | 209 | 1 |
| (nebivolol + valsartan) - Drug Profile | 210 | 2 |
| Product Description | 210 | 1 |
| Mechanism of Action | 210 | 1 |
| R&D Progress | 210 | 2 |
| (olmesartan medoxomil + rosuvastatin calcium) - Drug Profile | 212 | 1 |
| Product Description | 212 | 1 |
| Mechanism of Action | 212 | 1 |
| R&D Progress | 212 | 1 |
| (pitavastatin + valsartan) - Drug Profile | 213 | 1 |
| Product Description | 213 | 1 |
| Mechanism of Action | 213 | 1 |
| R&D Progress | 213 | 1 |
| A-11 - Drug Profile | 214 | 1 |
| Product Description | 214 | 1 |
| Mechanism of Action | 214 | 1 |
| R&D Progress | 214 | 1 |
| A1M-001 - Drug Profile | 215 | 1 |
| Product Description | 215 | 1 |
| Mechanism of Action | 215 | 1 |
| R&D Progress | 215 | 1 |
| AF-130 - Drug Profile | 216 | 1 |
| Product Description | 216 | 1 |
| Mechanism of Action | 216 | 1 |
| R&D Progress | 216 | 1 |